BIOCLONAL
![logo bioclonal](/sites/default/files/2024-10/1%20BioClonal%20Primary%20Logo.png)
Contact information
- Biodrugs
- Biomarkers
- Drug discovery
- Inflammatory diseases
- Immunology
- Ophtalmology and optometry
- Oncology
- Central nervous system
BioClonal S.L. is a biotechnology company that seeks to be a benchmark in the field of immunization. They develop monoclonal antibodies for use in human therapy, which devises an in vivo technology platform of its creation: RedMabs. They wnat to contribute all our knowledge to the ecosystem so that together can generate btter drugs and improve people´s quality of life.
Our activity fits in research and experimental development in biotechnology. Specifically, the company focuses on the discovery phase, from the conception of the idea to the sequence of the base monoclonal or the purified antibody. Today, the objective is to develop a platform for the discovery of antibodies for use in human therapy, through their exclusive technological platform, and to be the partner of other platforms at a international level.
Monoclonal antibodies for use in human therapy.
Drug Disovery: Our business model is bases on long-term collaboration so that use of our technology enables the generation of antibodies.